Meet with… PATH

Sep 8 2016

PATH is the leader in global health innovation. An international nonprofit organization, PATH saves lives and improves health, especially among women and children. PATH accelerates innovation across five platforms - vaccines, drugs, diagnostics, devices, and system and service innovations - that harness their entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs.

PATH works with companies to create market-based solutions through tailored partnership opportunities that deliver measurable impact. PATH matches each company's resources and expertise with their unique strengths to accelerate the next generation of lifesaving innovations, creating better health and opportunity for all.

Partnering with PATH is a smart investment that can yield significant social impact. Companies choose to work with PATH because of their:

  • Focus on high-impact, large-scale, sustainable approaches - and measurable results.
  • Proven technical and market expertise.
  • History of successful partnership with the private sector that dates from their founding in 1977.
  • Extensive in-country networks in more than 70 countries around the world.
  • International reputation as a trusted and influential convener and translator and their ability to mobilize partners across borders, sectors, and disciplines.
  • Major funders include the Bill & Melinda Gates Foundation; the US government; other governments, other nonprofit organizations, and multilateral agencies such as the World Health Organization; individuals; and interest from investments.

Headquartered in Seattle, Washington, PATH has 1,300 employees, 1,400 partners worldwide, and an annual budget of US$300 million. Visit for more details. If your company has technologies with applications in low- and middle-income countries, apply to meet one-on-one with PATH.

Dr. David Shoultz, program leader, Drug Development and Devices and Tools programs at PATH, will be in attendance on Thursday, September 8, to provide an overview presentation on PATH's areas of interest and keys to solving global health issues.

David and other PATH representatives will meet with a handful of preapproved applicants after the presentation.

10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and been approved. The application period ended on August 3rd.

PATH Participating Representative:
David Shoultz, Ph.D., MS, MBA | Global Program Leader, Drug Development and Devices and Tools, PATH
David Shoultz, Ph.D., MS, MBA, directs two of PATH's product development programs: the Drug Development program, which seeks to discover, develop, and deliver safe, effective, and affordable treatments for neglected diseases, and the Devices and Tools program, which focuses on advancing appropriate, affordable, and accessible technologies to improve the health of underserved populations.
Prior to joining PATH in 2014, Dr. Shoultz served as the director of grantee and partner engagement and as a member of the leadership team at the Bill & Melinda Gates Foundation. In this role, he led an effort to strengthen the foundation's relationships with its partner organizations to facilitate ongoing interactions and help achieve maximum impact. Previously, he served as a deputy director in the foundation's Global Health Program, Infectious Disease, where he was central to strategy, planning, and management for four strategic program teams, including malaria, enteric diseases, pneumonia, and the neglected tropical diseases.
Prior to his roles at the foundation, Dr. Shoultz worked as a member of the senior management team for a number of clinical research organizations participating in the development of new medicines, including PPD Development, PRA International, and Biomedical Systems. He has been a member of the affiliate faculty for the departments of Global Health and Epidemiology at the University of Washington since 2000 and sits on the board of the Geneva Foundation, where he also serves as the inaugural chair of the Scientific Advisory Committee. Dr. Shoultz earned his Ph.D. and MS from the School of Public Health and Community Medicine at the University of Washington, where he also obtained his BSN. He holds an MBA from the Albers School of Business and Economics at Seattle University, where he is a faculty member in the Executive MBA Program.
David Shoultz leads our work in drug development and in devices and tools.
Connect with David: Connect on LinkedIn

$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 7th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on August 3rd. Your application will be reviewed and you will be notified of acceptance on August 19th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.

About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.

329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It